Monitor upcoming Phase 1/2 data readouts in 1H26, particularly from RESET-SLE and RESET-SSc, which could inform registrational pathways and potentially catalyze investor interest despite lack of near-term revenue.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 23 $2.82entry
- T+1 · 8mo ago −5.32%α −4.96% · $2.67
- T+5 · 8mo ago −12.41%α −8.85% · $2.47
- T+20 · 7mo ago +10.99%α +3.57% · $3.13
- T+60 · 5mo ago +0.71%α −12.35% · $2.84
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash position of $133.6 million, sufficient to fund operations into Q4 2026. The company reiterated key clinical milestones for rese-cel, including complete Phase 1/2 data readouts in 1H26 and a planned BLA submission for myositis in 2027.
Key Financial Metrics
Key Facts
- R&D expenses increased to $36.2M (Q4 2025) from $25.5M (Q4 2024); full-year R&D rose to $142.7M from $97.2M.
- G&A expenses decreased to $6.4M (Q4 2025) from $8.3M (Q4 2024).
- Cash, cash equivalents, and short-term investments totaled $133.6M as of December 31, 2025, down from $164.0M a year prior.
- Company raised an additional $30.0M in Q1 2026 via ATM sales and warrant exercises.
- Cash runway expected through Q4 2026.
- Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG trials expected in 1H26.
- BLA submission for rese-cel in myositis anticipated in 2027 based on 17-patient registrational cohort.
Financial Impact
Increased R&D spend by $45.5M year-over-year; net loss widened to $167.9M in 2025 from $115.9M in 2024.
Risk Factors
- High cash burn with no approved products; dependent on successful clinical outcomes and future financing.
- Clinical timelines are forward-looking and subject to delays; no guarantee that data will support BLA submission or approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260280 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers